Although the mechanism by which inactivation of GPR35 attenuates Ang II–induced hypertension remains unclear, this suggests that targeting GPR35 could be a novel target in the therapeutic control of blood pressure, most obviously through the use of GPR35 antagonists. The gene discussed is GPR35; the disease is hypertensive disorder.